

ITP, immune thrombocytopenia; MDS, myelodysplasia; DIC,

💧 Extracorporeal circuit



URGENT CARE

disseminated intravascular coagulation; HLH, hemophagocytic lymphohistiocytosis; TTP, thrombotic thrombocytopenia purpura; TMA, thrombotic microangiopathy



de novo thrombocytopenia occurring in hospital

	CAUSES ACCORDING TO MECHANISM			
	Decreased Production	Increased Destruction	Sequestration	
ERGENCY ROOM	Alcohol	ITP TTP	Cirrhosis	
▲ TTP	(viral)	Drugs		

*

ITP with bleed

Alcohol use

EM

DIAGNOSTIC CLUES

ADDITIONAL FINDINGS	CONSIDERATIONS	ADDITIONAL FINDINGS	CONSIDERATIONS
Anemia	TTP Evans syndrome Babesiosis	Pancytopenia	B12 deficiency, hypersplenism, AA and others
Elevated PT, PTT	DIC, heparin, APS	Neutrophilia, left shift, toxic neutrophils	Sepsis

PT, prothrombin time; PTT, partial thromboplastin time; APS, antiphospholipid syndrome; AA, aplastic anemia

CLINICAL PEARLS

Remember to rule out platelet clumping as a cause of thrombocytopenia by looking at a smear

New onset thrombocytopenia in hospitalized patient is almost always caused by drugs (especially heparin) or infection (with or without DIC)

Thrombocytopenia + thrombosis, consider DIC, APS, or HIT

ITP is a diagnosis of exclusion; once it is being considered, consider ordering HIV and HCV serologies per clinical practice guidelines



The **risk for bleeding** does not increase until the platelet count falls < $10 \times 109/L$, provided patient not taking antiplatelet agent or anticoagulant

Most surgeries can be carried out with platelet count > 50 x 10^{9} L, with exception of neurological procedures, which require platelet count >80-100 x 10⁹/L



PROXIMATE **MECHANISMS**

Different mechanisms can lead to thrombocytopenia, including:

- Platelet clumping in vitro, caused by EDTA-dependent antibodies
- Decreased production, most often associated with additional cytopenias, but may also occurs as isolated thrombocytopenia from alcohol use, viral infections, cirrhosis (the latter from decreased thrombopoietin production) or amegakaryocytic thrombocytopenia

Increased destruction

- In ITP, antibody-mediated phagocytosis
- In HIT, antibody-mediated platelet activation
- In TMA, consumption of platelets in microvessels

EVOLUTIONARY MECHANISMS

All vertebrates have platelets, though only mammals have anucleate platelets. In other vertebrate classes (fish, amphibians, reptiles and birds), the nucleated platelets are called thrombocytes. They can be hard to distinguish from white blood cells in the peripheral smear.



It is tempting to speculate that the presence of a nucleus and other organelles in the non-mammalian vertebrate thrombocyte provides the cell with a greater reparative capacity compared to the mammalian form and therefore may render the organism more resistant to developing thrombocytopenia.

The gene-environment mismatch

hypothesis explains some propensity to

- In infection, increased sequestration on endothelial surface
- Sequestration pooling of platelets in spleen

develop thrombocytopenia. Our genome is adapted to a period of time 10,000 years ago, and has not had time to catch up to cultural changes such as introduction of alcohol and medications such as heparin.



HISTORY OF MEDICINE

Platelets were discovered in 1877 by a famous French physician, Georges Hayem. Since the cells lacked a nucleus there was a lot of controversy over whether they represented a true cell type. In the 1890s, physicians recognized a connection between low platelet count and hemorrhagic tendency, and by 1910 had proven it using animal models of experimentally induced thrombocytopenia.

NOTES

ATTRIBUTIONS

Written by

Dr. William Aird

Input from

Dr. Stephen Stearns (Evolutionary Medicine)

Dr. John Harvey (Comparative Physiology)

Dr. Jane Maienschein & Dr. Kate McCord (History of Medicine)

